Memorial Sloan Kettering Cancer Center
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
Inclusion Criteria: * Histologic diagnosis of classical Hodgkin's lymphoma. Primary refractory or relapsed disease proven by biopsy at enrolling institution. * Be willing and able to provide written informed consent/assent for the trial. * Be ≥ 18 years of age on day of signing informed consent. * PET scan before initiating pembro-GVD have measurable disease based on Lugano 2014 criteria * Have a performance status of 0 or 1 on the ECOG Performance Scale * Demonstrate adequate organ function as defined in table below * Demonstrate adequate organ function as defined in table below. Hematologic…
Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.
Involved-site radiation therapy (ISRT) Patients with limited sites of disease prior to initiation of pembro-GVD are eligible to receive ISRT prior to ASCT or with pembrolizumab maintenance. n. ISRT to nodal based disease should be delivered in line with the guidelines provided by the International Lymphoma Radiation Oncology Group.